Published in Int J Cancer on April 15, 2001
Engineering of vault nanocapsules with enzymatic and fluorescent properties. Proc Natl Acad Sci U S A (2005) 1.35
Targeting vault nanoparticles to specific cell surface receptors. ACS Nano (2009) 1.13
Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS One (2011) 1.01
Vaults are dynamically unconstrained cytoplasmic nanoparticles capable of half vault exchange. ACS Nano (2010) 0.89
iTRAQ quantitative analysis of multidrug resistance mechanisms in human gastric cancer cells. J Biomed Biotechnol (2010) 0.87
Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression. Radiat Oncol (2009) 0.87
Intracellular Mono-ADP-Ribosylation in Signaling and Disease. Cells (2015) 0.85
Unimpaired dendritic cell functions in MVP/LRP knockout mice. Immunology (2003) 0.82
Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines. J Ovarian Res (2016) 0.82
Major vault protein regulates cell growth/survival signaling through oxidative modifications. Cell Signal (2015) 0.81
Telomerase as a useful target in cancer fighting-the breast cancer case. Tumour Biol (2013) 0.79
Sea urchin vault structure, composition, and differential localization during development. BMC Dev Biol (2005) 0.77
Association of single nucleotide polymorphisms in the MVP gene with platinum resistance and survival in patients with epithelial ovarian cancer. Oncol Lett (2016) 0.76
[Not Available]. J Oncol (2009) 0.75
Major vault protein in cardiac and smooth muscle. Receptors Clin Investig (2016) 0.75
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res (2001) 4.05
Two species of lysosomal organelles in cultured human fibroblasts. Cell (1979) 3.64
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol (1989) 2.89
The drug resistance-related protein LRP is the human major vault protein. Nat Med (1995) 2.78
The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A (1994) 2.71
Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res (1997) 2.67
Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A (1994) 2.52
Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science (1996) 2.35
The transport of lysosomal enzymes. J Supramol Struct (1977) 2.22
The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol (1999) 2.14
Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol (1986) 1.98
Direct demonstration of binding of a lysosomal enzyme, alpha-L-iduronidase, to receptors on cultured fibroblasts. Proc Natl Acad Sci U S A (1979) 1.97
Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol (2001) 1.94
Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci U S A (1975) 1.86
Tissue distribution of the multidrug resistance protein. Am J Pathol (1996) 1.84
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A (2000) 1.83
A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology (1997) 1.79
Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem (1998) 1.74
Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res (1994) 1.73
Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res (1999) 1.72
The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nat Genet (2000) 1.64
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol (1991) 1.64
The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium. J Immunol (1991) 1.63
Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol (2000) 1.62
MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci U S A (1999) 1.59
Vaults. III. Vault ribonucleoprotein particles open into flower-like structures with octagonal symmetry. J Cell Biol (1991) 1.57
Coated vesicles from rat liver and calf brain contain lysosomal enzymes bound to mannose 6-phosphate receptors. J Biol Chem (1983) 1.54
Assembly of vault-like particles in insect cells expressing only the major vault protein. J Biol Chem (2001) 1.54
Structure of the vault, a ubiquitous celular component. Structure (1999) 1.53
Vaults and telomerase share a common subunit, TEP1. J Biol Chem (1999) 1.50
Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci (1993) 1.49
The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG. Hum Mol Genet (2000) 1.48
Evidence that leukocyte function-associated antigen-1 is involved in recirculation and homing of human lymphocytes via high endothelial venules. J Immunol (1988) 1.47
Assay and purification of a solubilized membrane receptor that binds the lysosomal enzyme alpha-L-iduronidase. Arch Biochem Biophys (1982) 1.46
A cytotoxic analysis of antiseptic medication on skin substitutes and autograft. Br J Dermatol (2007) 1.45
Vaults. II. Ribonucleoprotein structures are highly conserved among higher and lower eukaryotes. J Cell Biol (1990) 1.42
Unimpaired immune functions after laparoscopic cholecystectomy. Surgery (1994) 1.39
Human kidney alpha-L-iduronidase: purification and characterization. Arch Biochem Biophys (1978) 1.39
RNA location and modeling of a WD40 repeat domain within the vault. RNA (2000) 1.37
Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). J Invest Dermatol (1999) 1.37
A physical complex of the Fanconi anemia proteins FANCG/XRCC9 and FANCA. Proc Natl Acad Sci U S A (1999) 1.32
Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer (1995) 1.32
Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest (2000) 1.32
Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. J Immunol (2000) 1.30
Vault ribonucleoprotein particles from rat and bullfrog contain a related small RNA that is transcribed by RNA polymerase III. J Biol Chem (1993) 1.28
Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer (1996) 1.27
Coated vesicles from rat liver and calf brain contain cryptic mannose 6-phosphate receptors. J Biol Chem (1983) 1.26
Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol (1999) 1.26
Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother (2005) 1.25
The relation of immune depression and B-cell stimulation during the development of delayed hypersensitivity to soluble antigens. Immunology (1977) 1.23
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res (2000) 1.21
Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res (1988) 1.21
Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res (2000) 1.20
Human natural killer T cells acquire a memory-activated phenotype before birth. Blood (2000) 1.20
Multiple human vault RNAs. Expression and association with the vault complex. J Biol Chem (2001) 1.18
Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol (1996) 1.17
Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol (2000) 1.16
P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood (1993) 1.16
The Telomerase/vault-associated protein TEP1 is required for vault RNA stability and its association with the vault particle. J Cell Biol (2001) 1.15
Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer (1995) 1.14
T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut (1997) 1.14
Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha. Ann Rheum Dis (2004) 1.13
The vault complex. Cell Mol Life Sci (2003) 1.12
Rosette-forming cells and the immunological response after DNCB, DNP-carrier and oxazolone sensitization. Immunology (1974) 1.12
The value of an assessment of erythema and increase in thickness of the skin reaction for a full appreciation of the nature of delayed hypersensitivity in the guinea pig. Int Arch Allergy Appl Immunol (1977) 1.11
Production of monoclonal antibodies defining guinea pig T-cell surface markers and a strain 13 Ia-like antigen: the value of immunohistological screening. Hybridoma (1985) 1.11
Multidrug resistance related molecules in human and murine lung. J Clin Pathol (2002) 1.10
Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res (1995) 1.10
Expression of lymphocyte homing receptor as a mechanism of dissemination in non-Hodgkin's lymphoma. Blood (1989) 1.09
Multidrug resistance gene (P-glycoprotein) expression in the human fetus. Am J Pathol (1992) 1.08
Immunohistochemical detection of P-glycoprotein in human tumor cells with a low degree of drug resistance. Int J Cancer (1989) 1.08
Preparative agarose gel electrophoresis for the purification of small organelles and particles. Anal Biochem (1986) 1.07
Acetyl coenzyme A: alpha-glucosaminide N-acetyltransferase. Evidence for a transmembrane acetylation mechanism. J Biol Chem (1985) 1.07
HPV 16 infection and progression of cervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int J Cancer (1998) 1.06
Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J Immunol Methods (2001) 1.06
PCR-based cystic fibrosis (CF) carrier screening in a first-year medical student biochemistry laboratory. Am J Hum Genet (1993) 1.06
The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer (1997) 1.05
Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br J Cancer (1991) 1.05
Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J Exp Med (1998) 1.04
Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood (1996) 1.04
Differences in the intrinsic capacity of peripheral blood mononuclear cells to produce tumor necrosis factor alpha and beta in patients with inflammatory bowel disease and healthy controls. Scand J Gastroenterol (1995) 1.04
Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res (1998) 1.04
Myelination in cerebellar slice cultures: development of a system amenable to biochemical analysis. J Neurosci Res (1993) 1.03
The relation between B-cell stimulation and delayed hypersensitivity. The effect of cyclophosphamide pretreatment on antibody production. Immunology (1977) 1.03
4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes. Clin Immunol (2010) 1.03
Central and peripheral action of suppressor cells in contact sensitivity in the guinea-pig. Immunology (1976) 1.03
Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer (2000) 1.02
Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor. Clin Dev Immunol (2007) 1.02
Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. Ann Oncol (2000) 1.01
Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance. Int J Cancer (1995) 1.00
Telomerase-associated protein TEP1 is not essential for telomerase activity or telomere length maintenance in vivo. Mol Cell Biol (2000) 1.00
Vaults are the answer, what is the question? Trends Cell Biol (1996) 1.00